Edgewise Therapeutics, INC Form 4 insider transactions

Joanne M. Donovan, CMO of Edgewise Therapeutics, reports the acquisition and disposition of company stock, including shares acquired through RSU vesting and sales to cover tax obligations.

Edgewise Therapeutics CEO Kevin Koch reports the acquisition and disposal of company stock, including sales to cover tax obligations related to vested Restricted Stock Units (RSUs).